#1
#1 out of 189.22%
health1h ago
Key facts: Amgen cites Lp(a) cut's heart benefits; joins Ember $27M
- Amgen joins Ember LifeSciences in a $27 million Series A to support Ember Cube 2 and real-time temperature monitoring.
- Jay Bradner says near-total Lp(a) cut could significantly lower heart attacks and deaths.
- The cooperation aims to scale Ember’s cold-chain logistics for biopharma applications.
- The deal reinforces Ember LifeSciences’ expanded Series A funding announced May 27, 2026.
- Amgen views Lp(a) reduction as potentially important for cardiovascular outcomes.
- TradingView News covered the development as part of its market updates.
- The collaboration centers on cardiovascular risk reduction using lipid-lowering strategies.
- Ember Cube 2 is part of the project’s refrigerated logistics and monitoring plan.
- The funding round totals $27 million for Ember LifeSciences.
- Amgen’s involvement marks collaboration with a biotech logistics platform.
Vote 0